Amin Elashker, DO
Internal Medicine · Danbury, CTNPI 1093794182
Payments from drug & device makers
Across 313 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$901
- Novo Nordisk$694
- GSK$497
- AstraZeneca$471
- Pfizer$467
- Lilly USA, LLC$465
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,828100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $901 |
| Novo Nordisk | 39 | $694 |
| GSK | 25 | $497 |
| AstraZeneca | 29 | $471 |
| Pfizer | 26 | $467 |
| Lilly USA, LLC | 26 | $465 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $241 |
| Johnson & Johnson | 12 | $235 |
| Bayer | 9 | $174 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $151 |
| Amgen | 9 | $139 |
| Astellas Pharma US Inc | 6 | $128 |
| Novartis | 6 | $104 |
| Abbott | 5 | $98 |
| Medtronic(2 entities) | 4 | $96 |
| Boehringer Ingelheim | 5 | $95 |
| Amarin Pharma, Inc. | 5 | $88 |
| Currax Pharmaceuticals LLC | 6 | $86 |
| Amneal Pharmaceuticals LLC | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Biohaven Pharmaceuticals, Inc. | 4 | $66 |
| Exact Sciences | 3 | $64 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Eisai Inc. | 2 | $43 |
| Merck | 3 | $43 |
| Impel Pharmaceuticals Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Bausch Health US, LLC | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $21 |
| Medicomp Inc | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,828 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $58,748 |
| JardianceEmpagliflozin | 37 | $44,196 |
| OzempicSemaglutide | 27 | $29,251 |
| FarxigaDapagliflozin Propanediol | 21 | $28,062 |
| JanuviaSitagliptin Phosphate | 25 | $23,535 |
| TrulicityDulaglutide | 14 | $23,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $20,558 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,670 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,925 |
| Atorvastatin Calcium | 240 | $2,446 |
| Gabapentin | 193 | $2,282 |
| Rosuvastatin Calcium | 140 | $1,975 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $1,551 |
| SynthroidLevothyroxine Sodium | 14 | $1,462 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $467 | $58,74865 claims |
| Boehringer IngelheimJardiance | $95 | $44,19637 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $471 | $37,73336 claims |
| Novo NordiskOzempic | $694 | $29,25127 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $497 | $27,48348 claims |
| MerckJanuvia | $43 | $23,53525 claims |
| Lilly USA, LLCTrulicity | $465 | $23,22714 claims |
| AbbVieSynthroid | $901 | $1,46214 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $83 | $1,308133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Danbury
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.